Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Howard Univ. Washington DC NICHD CRS
mi
from
Washington,
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Howard Univ. Washington DC NICHD CRS
mi
from
Washington,
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
South Florida CDTC Ft Lauderdale NICHD CRS
mi
from
Fort Lauderdale, FL
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
South Florida CDTC Ft Lauderdale NICHD CRS
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Univ. of Florida Jacksonville NICHD CRS
mi
from
Jacksonville, FL
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Univ. of Florida Jacksonville NICHD CRS
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Univ. of Miami Ped. Perinatal HIV/AIDS CRS
mi
from
Miami, FL
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Univ. of Miami Ped. Perinatal HIV/AIDS CRS
mi
from
Miami, FL
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program
mi
from
Chicago, IL
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Rush Univ. Cook County Hosp. Chicago NICHD CRS
mi
from
Chicago, IL
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Rush Univ. Cook County Hosp. Chicago NICHD CRS
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Chicago Children's CRS
mi
from
Chicago, IL
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Chicago Children's CRS
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Children's Hospital
mi
from
New Orleans, LA
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Children's Hospital
mi
from
New Orleans, LA
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Children's Hosp. of Boston NICHD CRS
mi
from
Boston, MA
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Children's Hosp. of Boston NICHD CRS
mi
from
Boston, MA
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Boston Medical Center Ped. HIV Program NICHD CRS
mi
from
Boston, MA
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Boston Medical Center Ped. HIV Program NICHD CRS
mi
from
Boston, MA
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
WNE Maternal Pediatric Adolescent AIDS CRS
mi
from
Worcester, MA
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
WNE Maternal Pediatric Adolescent AIDS CRS
mi
from
Worcester, MA
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Michigan NICHD CRS
mi
from
Detroit, MI
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Michigan NICHD CRS
mi
from
Detroit, MI
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Rutgers - New Jersey Medical School CRS
mi
from
Newark, NJ
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Rutgers - New Jersey Medical School CRS
mi
from
Newark, NJ
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Bronx-Lebanon CRS
mi
from
Bronx, NY
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Bronx-Lebanon CRS
mi
from
Bronx, NY
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Jacobi Med. Ctr. Bronx NICHD CRS
mi
from
Bronx, NY
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Jacobi Med. Ctr. Bronx NICHD CRS
mi
from
Bronx, NY
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
SUNY Downstate Med. Ctr., Children's Hosp. at Downstate NICHD CRS
mi
from
Brooklyn, NY
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
SUNY Downstate Med. Ctr., Children's Hosp. at Downstate NICHD CRS
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Nyu Ny Nichd Crs
mi
from
New York, NY
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Nyu Ny Nichd Crs
mi
from
New York, NY
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Strong Memorial Hospital Rochester NY NICHD CRS
mi
from
Rochester, NY
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Strong Memorial Hospital Rochester NY NICHD CRS
mi
from
Rochester, NY
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
SUNY Stony Brook NICHD CRS
mi
from
Stony Brook, NY
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
SUNY Stony Brook NICHD CRS
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
DUMC Ped. CRS
mi
from
Durham, NC
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
DUMC Ped. CRS
mi
from
Durham, NC
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
St. Jude/UTHSC CRS
mi
from
Memphis, TN
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
St. Jude/UTHSC CRS
mi
from
Memphis, TN
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Texas Children's Hosp. CRS
mi
from
Houston, TX
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Texas Children's Hosp. CRS
mi
from
Houston, TX
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Seattle Children's Hospital CRS
mi
from
Seattle, WA
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Seattle Children's Hospital CRS
mi
from
Seattle, WA
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS
mi
from
San Juan,
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS
mi
from
San Juan,
Click here to add this to my saved trials
Study to Evaluate Bacterial Activity That Drives the Progression of Clinical Infection
Study to Evaluate Bacterial Activity That Drives the Progression of Clinical Infection
Status: Enrolling
Updated:  12/31/1969
UT Southwestern Medical Center at Dallas
mi
from
Dallas, TX
Study to Evaluate Bacterial Activity That Drives the Progression of Clinical Infection
Study to Evaluate Bacterial Activity That Drives the Progression of Clinical Infection
Status: Enrolling
Updated: 12/31/1969
UT Southwestern Medical Center at Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Diabetic Foot Infection Antibiotic Study
Surgical Management of Diabetic Foot Infections - The Role of Post-Operative Antibiotics
Status: Enrolling
Updated:  12/31/1969
Greenville Hospital System University Medical Center
mi
from
Greenville, SC
Diabetic Foot Infection Antibiotic Study
Surgical Management of Diabetic Foot Infections - The Role of Post-Operative Antibiotics
Status: Enrolling
Updated: 12/31/1969
Greenville Hospital System University Medical Center
mi
from
Greenville, SC
Click here to add this to my saved trials
Understanding and Addressing Variations in HAIs After Durable Ventricular Assist Device Therapy
Understanding and Addressing Variations in Healthcare-associated Infections (HAIs) After Durable Ventricular Assist Device Therapy
Status: Enrolling
Updated:  12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Understanding and Addressing Variations in HAIs After Durable Ventricular Assist Device Therapy
Understanding and Addressing Variations in Healthcare-associated Infections (HAIs) After Durable Ventricular Assist Device Therapy
Status: Enrolling
Updated: 12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated:  12/31/1969
Lac & Usc Medical Center
mi
from
Los Angeles, CA
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated: 12/31/1969
Lac & Usc Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated:  12/31/1969
UCLA CURE Digestive Diseases Center
mi
from
Los Angeles, CA
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated: 12/31/1969
UCLA CURE Digestive Diseases Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Vaccine Study Center
mi
from
Oakland, CA
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Vaccine Study Center
mi
from
Oakland, CA
Click here to add this to my saved trials
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated:  12/31/1969
Christiana Care Health Systems
mi
from
Newark, DE
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated: 12/31/1969
Christiana Care Health Systems
mi
from
Newark, DE
Click here to add this to my saved trials
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated:  12/31/1969
Dr Kiran C Patel Research Institute
mi
from
Tampa, FL
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated: 12/31/1969
Dr Kiran C Patel Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated:  12/31/1969
Idaho Falls Infectious Diseases PLLC
mi
from
Idaho Falls, ID
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated: 12/31/1969
Idaho Falls Infectious Diseases PLLC
mi
from
Idaho Falls, ID
Click here to add this to my saved trials
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated:  12/31/1969
Central Indiana Gastroenterology Group
mi
from
Anderson, IN
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated: 12/31/1969
Central Indiana Gastroenterology Group
mi
from
Anderson, IN
Click here to add this to my saved trials
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated:  12/31/1969
Chest, Infectious Diseases and Critical Care Assoc., PC
mi
from
Des Moines, IA
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated: 12/31/1969
Chest, Infectious Diseases and Critical Care Assoc., PC
mi
from
Des Moines, IA
Click here to add this to my saved trials
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated:  12/31/1969
University of Kentucky Medical Center
mi
from
Lexington, KY
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated: 12/31/1969
University of Kentucky Medical Center
mi
from
Lexington, KY
Click here to add this to my saved trials
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated:  12/31/1969
Henry Ford Health System
mi
from
West Bloomfield, MI
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated: 12/31/1969
Henry Ford Health System
mi
from
West Bloomfield, MI
Click here to add this to my saved trials
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated:  12/31/1969
Saint Luke's Hospital, Kansas City
mi
from
Kansas City, MO
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated: 12/31/1969
Saint Luke's Hospital, Kansas City
mi
from
Kansas City, MO
Click here to add this to my saved trials
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated:  12/31/1969
Saint James Healthcare
mi
from
Butte, MT
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated: 12/31/1969
Saint James Healthcare
mi
from
Butte, MT
Click here to add this to my saved trials
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated:  12/31/1969
Jersey Shore University Medical Center
mi
from
Neptune, NJ
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated: 12/31/1969
Jersey Shore University Medical Center
mi
from
Neptune, NJ
Click here to add this to my saved trials
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated:  12/31/1969
Mount Sinai Hosp
mi
from
New York, NY
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated: 12/31/1969
Mount Sinai Hosp
mi
from
New York, NY
Click here to add this to my saved trials
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated:  12/31/1969
All-Trials Clinical Research, LLC
mi
from
Winston-Salem, NC
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated: 12/31/1969
All-Trials Clinical Research, LLC
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated:  12/31/1969
Summa Health System
mi
from
Akron, OH
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated: 12/31/1969
Summa Health System
mi
from
Akron, OH
Click here to add this to my saved trials
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated:  12/31/1969
Remington-Davis Clinical Research
mi
from
Columbus, OH
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated: 12/31/1969
Remington-Davis Clinical Research
mi
from
Columbus, OH
Click here to add this to my saved trials
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated:  12/31/1969
Rapid City Regional Hospital
mi
from
Rapid City, SD
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated: 12/31/1969
Rapid City Regional Hospital
mi
from
Rapid City, SD
Click here to add this to my saved trials
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated:  12/31/1969
St. Luke's Episcopal Hospital
mi
from
Houston, TX
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated: 12/31/1969
St. Luke's Episcopal Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated:  12/31/1969
Scott & White Memorial Hospital
mi
from
Temple, TX
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated: 12/31/1969
Scott & White Memorial Hospital
mi
from
Temple, TX
Click here to add this to my saved trials
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated:  12/31/1969
MultiCare Health System Research Services
mi
from
Tacoma, WA
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated: 12/31/1969
MultiCare Health System Research Services
mi
from
Tacoma, WA
Click here to add this to my saved trials
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated:  12/31/1969
University of Calgary, Foothills Medical Center
mi
from
Calgary,
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Status: Enrolling
Updated: 12/31/1969
University of Calgary, Foothills Medical Center
mi
from
Calgary,
Click here to add this to my saved trials